vs
EXACT SCIENCES CORP（EXAS）与Shift4 Payments, Inc.（FOUR）财务数据对比。点击上方公司名可切换其他公司
Shift4 Payments, Inc.的季度营收约是EXACT SCIENCES CORP的1.4倍（$1.2B vs $878.4M），Shift4 Payments, Inc.净利率更高（3.4% vs -9.8%，领先13.2%），Shift4 Payments, Inc.同比增速更快（34.0% vs 23.1%），Shift4 Payments, Inc.自由现金流更多（$222.5M vs $120.4M），过去两年Shift4 Payments, Inc.的营收复合增速更高（29.6% vs 17.4%）
Exact Sciences是总部位于美国威斯康星州麦迪逊的分子诊断企业，专注于早期癌症检测领域。公司核心产品覆盖结直肠癌筛查与预防场景，其中Cologuard是全球首个获批的结直肠癌粪便DNA检测产品，同时还提供其他多种癌症的筛查服务及精准肿瘤检测解决方案。
Shift4 Payments是美国支付处理服务商，总部位于宾夕法尼亚州阿伦敦，1999年由贾里德·艾萨克曼创立。公司为零售、酒店、休闲、餐饮等行业超20万家商户提供支付处理服务，主营移动支付软硬件等商业技术，2020年于纽约证券交易所挂牌上市。
EXAS vs FOUR — 直观对比
营收规模更大
FOUR
是对方的1.4倍
$878.4M
营收增速更快
FOUR
高出10.9%
23.1%
净利率更高
FOUR
高出13.2%
-9.8%
自由现金流更多
FOUR
多$102.1M
$120.4M
两年增速更快
FOUR
近两年复合增速
17.4%
损益表 — Q4 FY2025 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $878.4M | $1.2B |
| 净利润 | $-86.0M | $40.2M |
| 毛利率 | 70.1% | — |
| 营业利润率 | -9.4% | 10.8% |
| 净利率 | -9.8% | 3.4% |
| 营收同比 | 23.1% | 34.0% |
| 净利润同比 | 90.1% | -65.3% |
| 每股收益（稀释后） | $-0.45 | — |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收EXASFOUR
| Q4 25 | $878.4M | $1.2B | ||
| Q3 25 | $850.7M | $1.2B | ||
| Q2 25 | $811.1M | $966.2M | ||
| Q1 25 | $706.8M | $848.3M | ||
| Q4 24 | $713.4M | $887.0M | ||
| Q3 24 | $708.7M | $909.2M | ||
| Q2 24 | $699.3M | $827.0M | ||
| Q1 24 | $637.5M | $707.4M |
净利润EXASFOUR
| Q4 25 | $-86.0M | $40.2M | ||
| Q3 25 | $-19.6M | $28.1M | ||
| Q2 25 | $-1.2M | $34.0M | ||
| Q1 25 | $-101.2M | $16.7M | ||
| Q4 24 | $-864.6M | $116.0M | ||
| Q3 24 | $-38.2M | $53.8M | ||
| Q2 24 | $-15.8M | $39.2M | ||
| Q1 24 | $-110.2M | $20.6M |
毛利率EXASFOUR
| Q4 25 | 70.1% | — | ||
| Q3 25 | 68.6% | — | ||
| Q2 25 | 69.3% | — | ||
| Q1 25 | 70.8% | — | ||
| Q4 24 | 69.0% | — | ||
| Q3 24 | 69.4% | — | ||
| Q2 24 | 69.8% | — | ||
| Q1 24 | 70.0% | — |
营业利润率EXASFOUR
| Q4 25 | -9.4% | 10.8% | ||
| Q3 25 | -3.0% | 9.7% | ||
| Q2 25 | -0.3% | 8.6% | ||
| Q1 25 | -13.6% | 3.0% | ||
| Q4 24 | -122.8% | 9.7% | ||
| Q3 24 | -5.6% | 8.8% | ||
| Q2 24 | -3.8% | 7.2% | ||
| Q1 24 | -16.7% | 3.0% |
净利率EXASFOUR
| Q4 25 | -9.8% | 3.4% | ||
| Q3 25 | -2.3% | 2.4% | ||
| Q2 25 | -0.1% | 3.5% | ||
| Q1 25 | -14.3% | 2.0% | ||
| Q4 24 | -121.2% | 13.1% | ||
| Q3 24 | -5.4% | 5.9% | ||
| Q2 24 | -2.3% | 4.7% | ||
| Q1 24 | -17.3% | 2.9% |
每股收益（稀释后）EXASFOUR
| Q4 25 | $-0.45 | — | ||
| Q3 25 | $-0.10 | — | ||
| Q2 25 | $-0.01 | — | ||
| Q1 25 | $-0.54 | — | ||
| Q4 24 | $-4.69 | — | ||
| Q3 24 | $-0.21 | — | ||
| Q2 24 | $-0.09 | — | ||
| Q1 24 | $-0.60 | — |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $964.7M | $964.0M |
| 总债务越低越好 | — | $4.5B |
| 股东权益账面价值 | $2.4B | $1.4B |
| 总资产 | $5.9B | $8.7B |
| 负债/权益比越低杠杆越低 | — | 3.15× |
8季度趋势，按日历期对齐
现金及短期投资EXASFOUR
| Q4 25 | $964.7M | $964.0M | ||
| Q3 25 | $1.0B | $1.5B | ||
| Q2 25 | $858.4M | $3.0B | ||
| Q1 25 | $786.2M | $1.2B | ||
| Q4 24 | $1.0B | $1.2B | ||
| Q3 24 | $1.0B | $1.4B | ||
| Q2 24 | $946.8M | $205.0M | ||
| Q1 24 | $652.1M | $522.9M |
总债务EXASFOUR
| Q4 25 | — | $4.5B | ||
| Q3 25 | — | $4.7B | ||
| Q2 25 | — | $3.7B | ||
| Q1 25 | — | $2.8B | ||
| Q4 24 | — | $2.8B | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
股东权益EXASFOUR
| Q4 25 | $2.4B | $1.4B | ||
| Q3 25 | $2.5B | $1.7B | ||
| Q2 25 | $2.5B | $1.6B | ||
| Q1 25 | $2.4B | $805.2M | ||
| Q4 24 | $2.4B | $806.6M | ||
| Q3 24 | $3.2B | $811.8M | ||
| Q2 24 | $3.2B | $700.8M | ||
| Q1 24 | $3.1B | $674.5M |
总资产EXASFOUR
| Q4 25 | $5.9B | $8.7B | ||
| Q3 25 | $5.9B | $9.0B | ||
| Q2 25 | $5.8B | $7.0B | ||
| Q1 25 | $5.7B | $5.0B | ||
| Q4 24 | $5.9B | $5.0B | ||
| Q3 24 | $6.7B | $5.0B | ||
| Q2 24 | $6.7B | $3.5B | ||
| Q1 24 | $6.4B | $3.4B |
负债/权益比EXASFOUR
| Q4 25 | — | 3.15× | ||
| Q3 25 | — | 2.83× | ||
| Q2 25 | — | 2.34× | ||
| Q1 25 | — | 3.53× | ||
| Q4 24 | — | 3.52× | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $151.7M | $223.7M |
| 自由现金流经营现金流 - 资本支出 | $120.4M | $222.5M |
| 自由现金流率自由现金流/营收 | 13.7% | 18.7% |
| 资本支出强度资本支出/营收 | 3.6% | 0.1% |
| 现金转化率经营现金流/净利润 | — | 5.56× |
| 过去12个月自由现金流最近4个季度 | $356.8M | $624.0M |
8季度趋势，按日历期对齐
经营现金流EXASFOUR
| Q4 25 | $151.7M | $223.7M | ||
| Q3 25 | $219.9M | $171.8M | ||
| Q2 25 | $89.0M | $141.9M | ||
| Q1 25 | $30.8M | $96.6M | ||
| Q4 24 | $47.1M | $145.4M | ||
| Q3 24 | $138.7M | $182.1M | ||
| Q2 24 | $107.1M | $116.1M | ||
| Q1 24 | $-82.3M | $56.7M |
自由现金流EXASFOUR
| Q4 25 | $120.4M | $222.5M | ||
| Q3 25 | $190.0M | $165.4M | ||
| Q2 25 | $46.7M | $141.0M | ||
| Q1 25 | $-365.0K | $95.1M | ||
| Q4 24 | $10.7M | $143.8M | ||
| Q3 24 | $112.6M | $180.1M | ||
| Q2 24 | $71.2M | $113.9M | ||
| Q1 24 | $-120.0M | $55.4M |
自由现金流率EXASFOUR
| Q4 25 | 13.7% | 18.7% | ||
| Q3 25 | 22.3% | 14.1% | ||
| Q2 25 | 5.8% | 14.6% | ||
| Q1 25 | -0.1% | 11.2% | ||
| Q4 24 | 1.5% | 16.2% | ||
| Q3 24 | 15.9% | 19.8% | ||
| Q2 24 | 10.2% | 13.8% | ||
| Q1 24 | -18.8% | 7.8% |
资本支出强度EXASFOUR
| Q4 25 | 3.6% | 0.1% | ||
| Q3 25 | 3.5% | 0.5% | ||
| Q2 25 | 5.2% | 0.1% | ||
| Q1 25 | 4.4% | 0.2% | ||
| Q4 24 | 5.1% | 0.2% | ||
| Q3 24 | 3.7% | 0.2% | ||
| Q2 24 | 5.1% | 0.3% | ||
| Q1 24 | 5.9% | 0.2% |
现金转化率EXASFOUR
| Q4 25 | — | 5.56× | ||
| Q3 25 | — | 6.11× | ||
| Q2 25 | — | 4.17× | ||
| Q1 25 | — | 5.78× | ||
| Q4 24 | — | 1.25× | ||
| Q3 24 | — | 3.38× | ||
| Q2 24 | — | 2.96× | ||
| Q1 24 | — | 2.75× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
EXAS
| Screening | $695.1M | 79% |
| Precision Oncology | $183.2M | 21% |
FOUR
| Payments Based Revenue | $788.8M | 66% |
| Other | $255.0M | 21% |
| Subscription And Other Revenues | $144.8M | 12% |
